Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients

Abstract

Objective: The use of fish oil-based emulsions as the sole source of fat for patients receiving parenteral nutrition (PN) has raised concerns for the development of essential fatty acid deficiency (EFAD), hindering its adoption into clinical practice. The purpose of the present study was to examine fatty acid profiles of patients receiving no enteral energy, while completely dependent on PN and an intravenous fish oil-based lipid emulsion, for onset of EFAD and maintenance of growth.

Patients and methods: Prospectively collected data from 10 patients were reviewed for evidence of EFAD, defined as a triene:tetraene ratio >0.2. Gestational age-adjusted z scores for length, growth, and head circumference at baseline were compared with the corresponding z scores at time of censoring. All of the patients received PN with a fish oil-based lipid emulsion at 1 g . kg . day as the sole source of fat energy for at least 1 month. The fish oil monotherapy was used under a compassionate use protocol.

Results: Median gestational age at the time of birth was 35 weeks, and median age at the start of treatment was 3.5 months. After a median time of 3.8 months on exclusive PN and fish oil-based lipid emulsion, none of the patients developed biochemical or clinical evidence of EFAD. z scores were not statistically different, indicating no growth impairment. Median direct bilirubin levels improved in 9 patients from 6.8 to 0.9 mg/dL (P = 0.009).

Conclusions: : When dosed appropriately, fish oil-based lipid emulsions contain sufficient amounts of essential fatty acids to prevent EFAD and sustain growth in patients who are completely dependent on PN.

Figures

Figure 1

Fatty acid profiles in patients on fish oil monotherapy demonstrated an increase in ω-3 fatty acids. Mead acid levels remained low, suggesting de novo lipogenesis was not increased. Median serum ω-3:ω-6 ratios (A) and mead acid levels (B) on a weekly basis from patients on exclusive parenteral nutrition and fish oil-based lipid emulsion. Whiskers extend to the extreme values.

Figure 1

Fatty acid profiles in patients on fish oil monotherapy demonstrated an increase in ω-3 fatty acids. Mead acid levels remained low, suggesting de novo lipogenesis was not increased. Median serum ω-3:ω-6 ratios (A) and mead acid levels (B) on a weekly basis from patients on exclusive parenteral nutrition and fish oil-based lipid emulsion. Whiskers extend to the extreme values.

Figure 2

Patients on fish oil monotherapy did not develop essential fatty acid deficiency (EFAD). Individual (A) and median (B) serum triene:tetraene ratios of patients exclusively on parenteral nutrition with fish oil-based lipid emulsion on a weekly basis. The dashed line indicates the lower limit for biochemical EFAD and whiskers extend to the extreme values.

Figure 2

Patients on fish oil monotherapy did not develop essential fatty acid deficiency (EFAD). Individual (A) and median (B) serum triene:tetraene ratios of patients exclusively on parenteral nutrition with fish oil-based lipid emulsion on a weekly basis. The dashed line indicates the lower limit for biochemical EFAD and whiskers extend to the extreme values.

Figure 3

Patients on fish-oil monotherapy did not exhibit growth impairment. Median Z-scores for length (A), weight (B) and head circumference (C) adjusted for gestational age at baseline (T=0) and at the time of censoring (End), showing no significant differences (P=0.236, P=0.932 and P=0.138, respectively). The solid bar within the box represents the median value; upper boundary of the box, the 75th percentile; lower boundary of the box, 25th percentile. Whiskers extend to the extreme values.

Figure 3

Patients on fish-oil monotherapy did not exhibit growth impairment. Median Z-scores for length (A), weight (B) and head circumference (C) adjusted for gestational age at baseline (T=0) and at the time of censoring (End), showing no significant differences (P=0.236, P=0.932 and P=0.138, respectively). The solid bar within the box represents the median value; upper boundary of the box, the 75th percentile; lower boundary of the box, 25th percentile. Whiskers extend to the extreme values.

Figure 3

Patients on fish-oil monotherapy did not exhibit growth impairment. Median Z-scores for length (A), weight (B) and head circumference (C) adjusted for gestational age at baseline (T=0) and at the time of censoring (End), showing no significant differences (P=0.236, P=0.932 and P=0.138, respectively). The solid bar within the box represents the median value; upper boundary of the box, the 75th percentile; lower boundary of the box, 25th percentile. Whiskers extend to the extreme values.